Genetic testing is a method to investigate genes in order to comprehend anomalies such as malignant tumor and cystic fibrosis, through the procedures of laboratory-developed tests and direct-to-consumer models, which have notably risen. The use of genetic tests in clinics and by consumers is increasing rapidly, while the market is smoothed by the regulatory challenges impinging upon authorities such as the FDA and EMA who find it difficult to keep up with such a pace of technological breakthroughs.
Key Growth Drivers and Opportunities
Rise in Incidence of Genetic Disorders: One of the main factors that are propelling the genetic testing market is the increasing frequency of genetic diseases and cancers, as well as a rising understanding and openness to personalized medicine. Besides that, the development of various fields and progress in technology concerning genetic testing, especially in cancer, are leading to the increased genetic testing market.
Challenges
Genetic testing market cannot be large as the gene tests are very expensive, the rules and regulations are complicated and there are some ethical issues particularly concerning data privacy and genetic discrimination. Also, genetic test adoption suffers from the inconsistency of the test’s accuracy, the lack of standardized guidelines, and little awareness in developing regions. Furthermore, the market is limited by the slow regulatory consent for the innovative technologies.
Innovation and Expansion
Mass General Brigham has launched a Genetic Test to Determine Risk for Eight Cardiovascular Disorders
In September 2025, Mass General Brigham Personalized Medicine and the Massachusetts General Hospital’s Cardiovascular Disease Prevention Center and Center for Genomic Medicine have announced the availability of an innovative genetic test that estimates an individual’s inherited risk for eight chronic cardiovascular conditions. The clinician-ordered test is now available to patients for self-pay.
The test, created in conjunction with Broad Clinical Labs and the Mass General Brigham Laboratory for Molecular Medicine (LMM), combines advanced genomic insights with clinical-grade reporting to provide a complete picture of a patient’s hereditary cardiovascular disease risk.
Bupa launches Medication Check DNA test
In July 2025, Bupa, a leading healthcare provider, has released Medication Check, a DNA testing tool that is part of a new suite of My Genomic Health tests, following its successful trial. The pilot discovered that 99% of people are genetically sensitive to common medications, which could lead to higher side effects, decreased effectiveness, or safety problems.
In response, Bupa has developed the Medication Check, a saliva test that determines which medications are most likely to be beneficial, which have a higher risk of harmful side effects, and, most importantly, which medications will not work for an individual based on their genome sequence.
Inventive Sparks, Expanding Markets
The key players operating the genetic testing market 23andMe, Abbott Laboratories Inc., Bio-Rad Laboratories, F. Hoffmann-La Roche Ltd., Danaher Corporation (Cepheid), Genesis Healthcare, Illumina Inc., Luminex Corporation, Eurofins Scientific SE (Eurofins), and Myriad Genetics Inc.
About Author:
Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.